- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/00 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Patent holdings for IPC class C07D 295/00
Total number of patents in this class: 226
10-year publication summary
|
4
|
10
|
8
|
8
|
4
|
5
|
5
|
6
|
1
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4826 |
7 |
| Janssen Pharmaceutica N.V. | 3358 |
7 |
| Merck Sharp & Dohme LLC | 3732 |
7 |
| BASF SE | 21098 |
6 |
| Merck Sharp & Dohme Corp. | 2189 |
5 |
| Boehringer Ingelheim International GmbH | 4636 |
5 |
| The Regents of the University of California | 20303 |
4 |
| Enanta Pharmaceuticals, Inc. | 435 |
4 |
| Meiji Seika Pharma Co., Ltd. | 254 |
4 |
| Theravance Biopharma R&D IP, LLC | 453 |
4 |
| The Trustees of Columbia University in the City of New York | 3604 |
3 |
| The Trustees of the University of Pennsylvania | 4390 |
3 |
| Abbvie Inc. | 1817 |
3 |
| Novartis AG | 10612 |
2 |
| Merck Sharp & Dohme B.V. | 780 |
2 |
| Union Carbide Corporation | 257 |
2 |
| Commissariat à l'énergie atomique et aux energies alternatives | 10954 |
2 |
| Cytokinetics, Inc. | 280 |
2 |
| Fondazione Istituto Italiano di Tecnologia | 609 |
2 |
| Gilead Sciences, Inc. | 2106 |
2 |
| Other owners | 150 |